Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond
The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Abstract
Neuroprotective drugs tested in clinical trials, particularly those that block N-methyl-D-aspartate-sensitive glutamate receptors (NMDARs), have failed miserably in large part because of intolerable side effects. However, one such drug, memantine, was recently approved by the European Union and the US FDA for the treatment of dementia following our group's discovery of its clinically tolerated mechanism of action. Here, we review the molecular basis for memantine efficacy in neurological diseases that are mediated, at least in part, by overactivation of NMDARs, producing excessive Ca(2+) influx through the receptor's associated ion channel and consequent free-radical formation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The discrepancy in ketamine IC50 values between these two studies might be explained by the concentration of agonist used (50 μM versus 1 mM glutamate), as higher agonist concentrations allow non-competitive antagonists, e.g. ketamine, to block more effectively due to a greater number of open channels”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Lipton, 2006
Citations
Cites
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972 · cited 1×
“D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK293 and N1E-115 cell systems in a non-competitive manner.”
BackgroundAlzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Magnesium gates glutamate-activated channels in mouse central neurones
Nowak, L., Bregestovski, P., Ascher, P., Herbet, A., & Prochiantz, A. (1984) · Nature · doi:10.1038/307462a0 · Cited by 4,043
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,139 · cited 1×
“The NR2 family of NMDAR subunits contains a binding site for glutamate, the endogenous agonist, whereas the NR1 subunit binds glycin”
BackgroundVoltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones
Mayer, M. L., Westbrook, G. L., & Guthrie, P. B. (1984) · Nature · doi:10.1038/309261a0 · Cited by 2,893
Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
Epstein, F. H., Lipton, S. A., & Rosenberg, P. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300907 · Cited by 2,658 · cited 1×
“kon Channel + MEM ↔ Channel–MEM (Blocked channel) (1)”
Self-citationMolecular diversity of glutamate receptors and implications for brain function
Nakanishi, S. (1992) · Science · doi:10.1126/science.1329206 · Cited by 2,543
Heteromeric NMDA receptors: molecular and functional distinction of subtypes
Monyer, H., Sprengel, R., Schoepfer, R., Herb, A., Higuchi, M., Lomeli, H., Burnashev, N., Sakmann, B., & Seeburg, P. H. (1992) · Science · doi:10.1126/science.256.5060.1217 · Cited by 2,541
Lipton, S. A., Choi, Y.-B., Pan, Z.-H., Lei, S. Z., Chen, H.-S. V., Sucher, N. J., Loscalzo, J., Singel, D. J., & Stamler, J. S. (1993) · Nature · doi:10.1038/364626a0 · Cited by 2,433
Self-citationNitric oxide mediates glutamate neurotoxicity in primary cortical cultures.
Dawson, V. L., Dawson, T. M., London, E. D., Bredt, D. S., & Snyder, S. H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.14.6368 · Cited by 2,174
Research works printed but not linked: 5
- Chen, H. -S. V. & Lipton, S. A. in Post Genomic Drug Discovery Research (ed. Huang, Z.) (John Wiley & Sons, Hoboken, NJ (in the press).
- Navia, B. A., Yiannoutsos, C., Ellis, R., Schifitto, G., Nath, A., Shriver, S., Millar, L. & Lipton, S. A. Memantine may prevent further cognitive decline in subjects with AIDS Dementia Complex with detectable CSF HIV RNA. Neurology 64 (Suppl. 1), A247–A238 (2005).
- Lipton, S. A., Rayudu, P. V., Choi, Y. -B., Sucher, N. J. & Chen, H. -S. V. in Prog Brain Res. (eds Mize, V., Dawson, T. M., Dawson, M. & Friedlander, M.) 73–82 (Elsevier, Amsterdam, 1998).
- Káradóttir, R., Cavelier, P., Bergersen, L. H. & Atwell, D. NMDA receptors in oligodendrocyte physiology and pathology. Nature (in the press).
- Micu, I. et al. NMDA receptors mediate Ca accumulation in central nervous system myelin during chemical ischemia. Nature (in the press).
Cited by
Items 401–500 of 943
Giustizieri, M., Cucchiaroni, M. L., Guatteo, E., Bernardi, G., Mercuri, N. B., & Berretta, N. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.122036 · Cited by 31
“…with excitotoxic cell death, including Parkinson’s disease, amyotrophic lateral sclerosis, Alzheimer’s disease, epilepsy, stroke, spasticity, convulsions, and vascular dementia (Fleischhacker et al., 1986; Ditzler, 1991; Sonkusare et al., 2005; Chen and Lipton, 2006; Volbracht et al., 2006).”
BackgroundInfluentialZahodne, L. B., & Fernandez, H. H. (2008) · CNS Spectrums · doi:10.1017/s1092852900017296 · Cited by 27
Aquilani, R., Costa, A. C., Maestri, R., Ramusino, M. C., Pierobon, A., Dossena, M., Solerte, S. B., Condino, A. M., Torlaschi, V., Bini, P., et al. (2020) · Nutrients · doi:10.3390/nu12061845 · Cited by 27
“In AD, NMDA receptors are continuously activated [50].”
BackgroundGutti, G., Leifeld, J., Ramakrishna, K., Bajad, N. G., Ganeshpurkar, A., Kumar, A., Krishnamurthy, S., Klein-Schmidt, C., Tapken, D., Hollmann, M., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115670 · Cited by 27
de Oliveira, L. T., Louzada, P. R., Mello, F. G. D., & Ferreira, S. T. (2010) · Neurochemical Research · doi:10.1007/s11064-010-0287-z · Cited by 32
“damage play a central role in Ab neurotoxicity [41, 42 ].”
BackgroundChe, A., Truong, D. T., FITCH, R. H., & LoTurco, J. J. (2015) · Cerebral Cortex · doi:10.1093/cercor/bhv168 · Cited by 28
Cytokine regulation by modulation of the NMDA receptor on astrocytes
Sühs, K., Gudi, V., Eckermann, N., Fairless, R., Pul, R., Skripuletz, T., & Stangel, M. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.07.016 · Cited by 27
Neuroprotective agents in schizophrenia and affective disorders
Krebs, M., Leopold, K., Hinzpeter, A., & Schaefer, M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.7.837 · Cited by 28
“Excitotoxicity is defined as excessive exposure to glutamate or overstimulation of NMDA receptors, leading to excessive Ca2+ influx, and has been implicated as one of the key features contributing to neuronal injury and cell death [16].”
BackgroundChen, Z.-L., Yu, H., Yu, W.-M., Pawlak, R., & Strickland, S. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200803107 · Cited by 28
“These side effects prevent their use in patients ( Kemp and McKernan, 2002 ; Lipton, 2006 ).”
BackgroundGuidi, M., Rani, A., Karic, S., Severance, B., Kumar, A., & Foster, T. C. (2015) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2015.07.015 · Cited by 28
“The idea that NMDAR activity contributes to neurotoxicity provides a basis for use of NMDAR antagonists to treat Alzheimer’s disease in order to limit the progression of cell loss (Rogawski and Wenk, 2003; Lipton, 2006).”
BackgroundChang, W., & Teng, J. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s155567 · Cited by 27
“It acts on the glutamatergic system by blocking NMDA receptors and inhibiting their overstimulation by glutamate.(11) Memantine has infrequent and mild drug-related adverse events, including hallucinations, fatigue, and headache.”
Schaefer, M., Sarkar, S., Theophil, I., Leopold, K., Heinz, A., & Gallinat, J. (2019) · Pharmacopsychiatry · doi:10.1055/a-0970-9310 · Cited by 27
“Memantine is approved for treatment of moderate to severe Alzheimer’s disease, improving cognition and memory function with a good tolerability profile, but has been also discussed as a possible neuroprotective agent in patients with schizophrenia [20, 21].”
BackgroundGhatak, S., Nakamura, T., & Lipton, S. A. (2023) · Frontiers in Neural Circuits · doi:10.3389/fncir.2023.1099467 · Cited by 27
“…recently developed modified aminoadamantane compounds (the class of drug that memantine falls into), including a lead drug candidate called NitroSynapsin (a.k.a. NitroMemantine, YQW-036, EM-036) (Lipton, 2006; Wang et al., 2006; Talantova et al., 2013; Takahashi et al., 2015; Ghatak et al., 2021a).”
BackgroundSelf-citationG6PD deficiency triggers dopamine loss and the initiation of Parkinson’s disease pathogenesis
Stykel, M. G., Siripala, S. V., Soubeyrand, E., Coackley, C. L., Lu, P., Camargo, S., Thevasenan, S., Figueroa, G. B., So, R. W. L., Stuart, E., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2024.115178 · Cited by 26
Perspectives on Cognitive Computers and Knowledge Processors
Wang, Y., Fariello, G., Gavrilova, M. L., Kinsner, W., Mizoguchi, F., Patel, S., Patel, D. A., Pelayo, F. L., Raskin, V., Shell, D. F., et al. (2013) · International Journal of Cognitive Informatics and Natural Intelligence · doi:10.4018/ijcini.2013070101 · Cited by 26
Poulsen, M. H., Lucas, S., Bach, T. B., Barslund, A. F., Wenzler, C., Jensen, C. B., Kristensen, A. S., & Strømgaard, K. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301602d · Cited by 26
Recla, J. M., & Sarantopoulos, C. D. (2009) · Medical Hypotheses · doi:10.1016/j.mehy.2009.01.052 · Cited by 26
“It has been suggested that excessive stimulation of glutamate receptors, particularly NMDARs, is responsible for the neurodegeneration associated with Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, human immunodeficiency virus (HIV)-associated dementia, multiple sclerosis, amyotrophic lateral sclerosi…”
BackgroundA Mutation in DAOA Modifies the Age of Onset in PSEN1 E280A Alzheimer’s Disease
Vélez, J. I., Rivera, D., Mastronardi, C. A., Patel, H. R., Tobón, C., Villegas, A., Cai, Y., Easteal, S., Lopera, F., & Arcos-Burgos, M. (2016) · Neural Plasticity · doi:10.1155/2016/9760314 · Cited by 25
“However, the success of memantine and other NMDARs has been limited in the clinical setting due to their low efficacy and side effects [44, 52, 53].”
BackgroundMitochondrial connection to ginsenosides
Wang, F., & Roh, Y. S. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01279-2 · Cited by 30
“According to recent researches, glutamate receptor-induced neuronal excitotoxicity has been considered as the most important reasons responsible for the central nervous system (CNS) (Lipton 2006; Szydlowska and Tymianski 2010).”
BackgroundMassetti, N., Russo, M., Franciotti, R., Nardini, D., Mandolini, G. M., Granzotto, A., Bomba, M., Pizzi, S. D., Mosca, A., Scherer, R., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210573 · Cited by 28
Subramanian, A., Tamilanban, T., Sekar, M., Begum, M. Y., Atiya, A., Ramachawolran, G., Wong, L. S., Subramaniyan, V., Gan, S. H., Rani, N. N. I. M., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1212376 · Cited by 26
“) conferred a neuroprotective property, since it is an NMDA antagonist, it improved the locomotor activity, memory and non-spatial learning while decreasing the levels of sodium and calcium ions (Lipton, 2006).”
BackgroundExtrasynaptic glutamate NMDA receptors: Key players in striatal function
Garcia-Munoz, M., López-Huerta, V. G., Carrillo‐Reid, L., & Arbuthnott, G. W. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.09.013 · Cited by 31
New oxapolycyclic cage amines with NMDA receptor antagonist and trypanocidal activities
Duque, M. D., Camps, P., Torres, E., Valverde, E., Sureda, F. X., López-Querol, M., Camins, A., Prathalingam, S. R., Kelly, J. M., & Vázquez, S. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.11.017 · Cited by 29
Lo, F., Blue, M. E., & Erzurumlu, R. S. (2015) · Journal of Neurophysiology · doi:10.1152/jn.00944.2015 · Cited by 25
“Its uncompetitive nature results in an effective blockade of chronic extrasynaptic NMDAR activity and displays minimal adverse effects (Chen and Lipton 2006; Hardingham and Bading 2010; Lipton 2006).”
BackgroundKulkarni, J., Thomas, N., Hudaib, A., Gavrilidis, E., Grigg, J., Tan, R., Cheng, J., Arnold, A., & Gurvich, C. (2018) · CNS Drugs · doi:10.1007/s40263-018-0506-8 · Cited by 25
Noble Gases Therapy in Cardiocerebrovascular Diseases: The Novel Stars?
Zhang, J., Liu, W., Bi, M., Xu, J.-W., Yang, H., & Zhang, Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.802783 · Cited by 26
Sacai, H., Sasaki‐Hamada, S., Sugiyama, A., Saitoh, A., Mori, K. J., Yamada, M., & Oka, J. (2014) · Neuroscience Research · doi:10.1016/j.neures.2014.02.002 · Cited by 25
da Silva, F. R., Batista, E. M., Gomez, M. V., Kushmerick, C., Silva, J. F. D., Cordeiro, M. N., Vieira, L. B., & Ribeiro, F. M. (2016) · Toxicon · doi:10.1016/j.toxicon.2016.01.056 · Cited by 26
“…extrasynaptic NMDARs could be a promising strategy to prevent neurodegeneration in AD and HD. Memantine is a non-competitive NMDAR antagonist with relatively rapid off-rate from the channel and also with strong voltage dependence (Chen and Lipton, 1997; Johnson and Kotermanski, 2006; Lipton, 2006).”
BackgroundImplications of Gliotransmission for the Pharmacotherapy of CNS Disorders
Rossi, D., Martorana, F., & Brambilla, L. (2011) · CNS Drugs · doi:10.2165/11593090-000000000-00000 · Cited by 26
Gao, X., Li, R., Luo, L., Zhang, D., Liu, Q., Zhang, J., & Mao, S. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154363 · Cited by 24
D-amino acids in normal ageing and pathogenesis of neurodegenerative diseases
Chervyakov, A. V., Gulyaeva, N. V., & Zakharova, M. N. (2011) · Neurochemical Journal · doi:10.1134/s1819712411020036 · Cited by 28
Towards Medication-Enhancement of Cognitive Interventions in Schizophrenia
Chou, H., Twamley, E. W., & Swerdlow, N. R. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25758-2_4 · Cited by 24
“…properties might have deleterious consequences in SZ patients, there is evidence that, in fact, memantine is neuroprotective (Kornhuber et al. 1994; Lipton 2006; Rogawski and Wenk 2003), welltolerated by SZ patients (de Lucena et al. 2009; Krivoy et al. 2008; Lieberman et al. 2009; Zdanys and…”
BackgroundAlzheimer’s disease in the zebrafish: where can we take it?
Caramillo, E. M., & Echevarria, D. J. (2017) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000284 · Cited by 26
Memantine and its benefits for cancer, cardiovascular and neurological disorders
Shafiei‐Irannejad, V., Abbaszadeh, S., Janssen, P. M. L., & Soraya, H. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174455 · Cited by 25
Deur, C., Agrawal, A. K., Baum, H., Booth, J., Bove, S. E., Brieland, J. K., Bunker, A. M., Connolly, C. J. C., Cornicelli, J. A., Dumin, J., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.05.083 · Cited by 24
NMDA receptor is involved in neuroinflammation in intracerebroventricular colchicine-injected rats
Sil, S., Ghosh, T., & Ghosh, R. (2016) · Journal of Immunotoxicology · doi:10.3109/1547691x.2015.1130760 · Cited by 24
“However, while memantine can block NMDA receptors, it also influences other receptors ( 7 nicotinic receptors) that probably help to ameliorate dementia by potentiating cholinergic mechanisms in the brain (Buisson & Bertrand 1998; Aracava et al. 2005; Chen & Lipton 2006).”
BackgroundFrølund, S. U., Bella, A., Kristensen, A. S., Ziegler, H. L., Witt, M., Olsen, C. A., Strømgaard, K., Franzyk, H., & Jaroszewski, J. W. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100886h · Cited by 26
Camins, A., Sureda, F. X., Junyent, F., Verdaguer, E., Folch, J., Beas‐Zárate, C., & Pallàs, M. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003781898 · Cited by 26
“Current knowledge of apoptotic pathways has led to the hypothesis that therapeutic action on more than one target should offer additional therapeutic benefits [6-9,11-13].”
BackgroundInfluentialSokolov, V. B., Махаева, Г. Ф., Aksinenko, A. Y., Grigoriev, V. V., Shevtsova, E. F., & Бачурин, С. О. (2017) · Russian Chemical Bulletin · doi:10.1007/s11172-017-1953-y · Cited by 23
Dahhan, N. Z. A., Cox, E., Nieman, B. J., & Mabbott, D. (2022) · Neuron · doi:10.1016/j.neuron.2022.04.009 · Cited by 25
Satoh, T., Stalder, R., McKercher, S. R., Williamson, R. E., Roth, G. P., & Lipton, S. A. (2015) · ASN NEURO · doi:10.1177/1759091415593294 · Cited by 24
Self-citationPBT2 inhibits glutamate-induced excitotoxicity in neurons through metal-mediated preconditioning
Johanssen, T., Suphantarida, N., Donnelly, P. S., Liu, X. M., Petrou, S., Hill, A. F., & Barnham, K. J. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.02.008 · Cited by 23
“The drug is clinically tolerated reportedly due to a faster “off-rate” (Adlard et al., 2008; Lipton, 2006) Unlike MK-801, Memantine has”
InfluentialKetamine Protects Gamma Oscillations by Inhibiting Hippocampal LTD
Huang, L., Yang, X., Huang, Y., Sun, E. Y., & Sun, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159192 · Cited by 24
“One of them is memantine, which is widely prescribed for patients diagnosed with moderate-to-severe AD [5].”
BackgroundSokolov, V. B., Aksinenko, A. Y., Горева, Т. В., Епишина, Т. А., Grigor´ev, V. V., ́yan, A. V. G., Vinogradova, D. V., Неганова, М. Е., Shevtsova, E. F., & Бачурин, С. О. (2016) · Russian Chemical Bulletin · doi:10.1007/s11172-016-1461-5 · Cited by 23
Menuet, C., Borghgraef, P., Voituron, N., Gestreau, C., Gielis, L., Devijver, H., Dutschmann, M., LEUVEN, F. V., & Hilaire, G. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.01.012 · Cited by 23
“On the short term (4 h isoflurane), the massive activation of KF neurons induced excessive calcium influx, free radical formation (Chen and Lipton, 2006; Lipton, 2006), excitotoxicity and subsequent KF alteration, as assessed by delayed inspiratory off-switch and prolonged chest EMG in both Tau.”
BackgroundNakamura, T., Gu, Z., & Lipton, S. A. (2007) · Aging Cell · doi:10.1111/j.1474-9726.2007.00284.x · Cited by 24
“While many factors determine a drug’s clinical efficacy and tolerability, it appears that the relatively rapid off-rate is a predominant factor in memantine’s tolerability in contrast to other NMDA-type receptor antagonists (reviewed Chen & Lipton, 2006; Lipton, 2006).”
BackgroundResultSelf-citationBicca, M. A., Figueiredo, C. P., Piermartiri, T., Meotti, F. C., Bouzon, Z. L., Tasca, C. I., Medeiros, R., & Calixto, J. Β. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.06.038 · Cited by 26
Sułkowski, G., Dąbrowska‐Bouta, B., & Strużyńska, L. (2013) · BioMed Research International · doi:10.1155/2013/186068 · Cited by 24
“Indeed, it has been shown that blocking of NMDARs decreases the feedback of synaptically released glutamate [9, 12, 26, 47].”
BackgroundNeuronal Death and Neuroprotection: A Review
Repici, M., Mariani, J., & Borsello, T. (2007) · Methods in molecular biology · doi:10.1007/978-1-59745-504-6_1 · Cited by 23
Lu, H., Chen, S., Nie, Q., Xue, Q., Fan, H., Wang, Y., Fan, S., Zhu, J., Shen, H., Li, H., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112233 · Cited by 23
Ketamine alleviates NMDA receptor hypofunction through synaptic trapping
Villega, F., Fernandes, A., Jézéquel, J., Uyttersprot, F., Bénac, N., Zenagui, S., Bastardo, L., Gréa, H., Bouchet, D., Villetelle, L., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.06.028 · Cited by 25
“22–25 Common explanations include the fact that targeting NMDAR channel properties often comes with major adverse effects, and NMDAR agonists and antagonists elicit a variety or responses at the synaptic, network, and behavioral levels.”
BackgroundRegulation of human serine racemase activity and dynamics by halides, ATP and malonate
Marchetti, M., Bruno, S., Campanini, B., Bettati, S., Peracchi, A., & Mozzarelli, A. (2014) · Amino Acids · doi:10.1007/s00726-014-1856-2 · Cited by 22
“Direct pharmacological targeting of NMDARs was shown to produce side effects that are not compatible with the long-term treatment of these diseases (Lipton 2006; Molla et al. 2006).”
BackgroundCrosson, L. A., Kroes, R. A., Moskal, J. R., & Linsenmeier, R. A. (2009) · PubMed Central · Cited by 22
In vivo phenotypic screening: clinical proof of concept for a drug repositioning approach
Ciallella, J. R., & Reaume, A. G. (2017) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2017.04.001 · Cited by 24
Tuttle, A., Riera, J. J., & Mori, Y. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007455 · Cited by 23
“The NMDAR study shows that NMDAR inhibitors can indeed have a neuroprotective effect, as reported in clinical trials [48].”
BackgroundDąbrowska‐Bouta, B., Strużyńska, L., Sidoryk‐Wȩgrzynowicz, M., & Sułkowski, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111330 · Cited by 26
“In MS, excitotoxicity is caused by different mechanisms, but the ultimate consequence is neuronal damage due to overstimulation of glutamate receptors (GluRs), especially of NMDA subtype receptors [11].”
BackgroundMeyners, C., Baud, M. G. J., Fuchter, M. J., & Meyer‐Almes, F. (2014) · Analytical Biochemistry · doi:10.1016/j.ab.2014.05.014 · Cited by 23
“, memantine, an inhibitor of NMDA receptor, reduce toxicity by a fast dissociation rate [41].”
BackgroundPhaseic Acid, an Endogenous and Reversible Inhibitor of Glutamate Receptors in Mouse Brain
Hou, S., Jiang, S. X., Zaharia, L. I., Han, X., Benson, C. L., Slinn, J., & Abrams, S. R. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.756429 · Cited by 22
“It has been suggested that compounds with properties to reversibly and uncompetitively block NMDARs are the preferred candidates for development as therapeutics against stroke (9).”
BackgroundInfluentialMemantine in Moderately-Severe-to-Severe Alzheimerʼs Disease: A Postmarketing Surveillance Study
Clerici, F., Vanacore, N., Elia, A., Alegiani, S. S., Pomati, S., Cas, R. D., Raschetti, R., & Mariani, C. B. (2009) · Drugs & Aging · doi:10.2165/00002512-200926040-00003 · Cited by 23
“Memantine, an uncompetitive NMDA receptor antagonist licensed for the treatment of AD, has been shown to both inhibit excitotoxicity during chronic glutaminergic stimulation and to allow normal glutaminergic neurotransmission under physiological conditions.([2]) Several randomized clinical trials (RCTs) included in a…”
BackgroundThe Evolution of AChE Inhibitors in Alzheimer's Disease: From Single‐Target to Multi‐Target Ligands
Mehta, N. V., Kapadia, A., Khambete, M., & Abhyankar, A. N. (2025) · ChemBioChem · doi:10.1002/cbic.202500053 · Cited by 22
Zhang, Z., Zhang, L., Chen, J., Cao, Y., Qu, M., Lin, X., Han, Z., & Ji, X. (2018) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2017.12.041 · Cited by 22
A study of methylprednisolone neuroprotection against acute injury to the rat spinal cord in vitro
Sámano, C., Kaur, J., & Nistri, A. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.12.003 · Cited by 25
“Thus, neuroprotection against secondary injury is a major therapeutic target (York et al., 2013; Cox et al., 2014) to preserve the spinal gray (Lipton, 2006; Sámano et al., 2012) and white matter containing the long-fiber tracts (Kanellopoulos et al., 2000; Lee et al., 2008; Margaryan et al.,…”
Meneghetti, E., Gasperini, L., Virgilio, T., Moda, F., Tagliavini, F., Benetti, F., & Legname, G. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1505-6 · Cited by 21
Verschuuren, M., Verstraelen, P., Barriga, G. G.-D., Cilissen, I., Coninx, E., Verslegers, M., Larsen, P. H., Nuydens, R., & Vos, W. H. D. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0741-3 · Cited by 23
“The score indicated that memantine treatment had only a slight negative impact on neuronal connectivity in comparison with MK801, which may be the result of memantine having a shorter dwell time on the NMDA-R then MK801 [41].”
BackgroundInfluentialFrom understanding synaptic plasticity to the development of cognitive enhancers
Cheung, Z. H., & Ip, N. Y. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001537 · Cited by 22
“This special property of memantine allows it to preferentially bind to NMDARs that are open for a prolonged period, without interfering with the normal physiological function of the receptor (Lipton, 2006 ; Monti & Contestabile, 2009 ; Rammes et al. 2008).”
BackgroundInfluentialComputational approaches for innovative antiepileptic drug discovery
Talevi, A. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1216965 · Cited by 23
“Memantine (Figure 2) constitutes a good example of the potential benefits of low-affinity multi-target ligands on CNS disorders [99,100].”
BackgroundMolinaro, G., Battaglia, G., Riozzi, B., Menna, L. D., Rampello, L., Bruno, V., & Nicoletti, F. (2009) · Brain Research · doi:10.1016/j.brainres.2009.02.016 · Cited by 21
Antiseizure medication discovery: Recent and future paradigm shifts
Talevi, A. (2022) · Epilepsia Open · doi:10.1002/epi4.12581 · Cited by 25
Rakovskaya, A., Erofeev, A., Vinokurov, E. K., Pchitskaya, E. I., Dahl, R. S., & Борисович, Б. И. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813973 · Cited by 21
“The pharmacological normalization of calcium signaling in neurons is a promising approach for the development of therapeutic agents, and its potential efficacy and applicability is demonstrated through the example of memantine [10]—a noncompetitive NMDA glutamate receptor antagonist.”
Lucido, M. J., & Dunlop, B. W. (2025) · Brain Sciences · doi:10.3390/brainsci15020161 · Cited by 23
“…a more selective blockade of neurons with high levels of tonic activity, such as GABAergic interneurons, preserving physiologic activity elsewhere [72] and reducing the cognitive and psychotomimetic effects of high trapping blockers like ketamine [73], which underlie its use as a drug of abuse.”
Lecointre, M., Vézier, C., Bénard, M., Ramdani, Y., Dupré, N., Brasse‐Lagnel, C., Henry, V., Roy, V., Marret, S., Gonzalez, B. J., et al. (2014) · Developmental Neurobiology · doi:10.1002/dneu.22232 · Cited by 22
Kinetic binding assays for the analysis of protein–ligand interactions
Meyer‐Almes, F. (2015) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2015.08.004 · Cited by 20
Dai, Q., Sheng, Z., Geiger, J. H., Castellino, F., & Prorok, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609087200 · Cited by 20
The Influence of Spin-Labeled Fluorene Compounds on the Assembly and Toxicity of the Aβ Peptide
Petrlová, J., Kálai, T., Maezawa, I., Altman, R., Ghimire, H., Hong, H., Bricarello, D. A., Parikh, A. N., Lorigan, G. A., Jin, L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035443 · Cited by 20
“In AD, accumulating evidence points to oxidative stress as the ultimate downstream component of Ab-induced toxicity [9,10].”
BackgroundLi, Y., Yang, Q., Zhang, K., Guo, Y., Li, X., Yang, L., Zhao, M., & Wu, Y. (2012) · NeuroToxicology · doi:10.1016/j.neuro.2012.09.009 · Cited by 21
“Over-activated NMDA receptors are permeable to Na+, K+, and Ca2+ ions, among which excess Ca2+ ions are linearly correlated with neuronal cell death triggered by intracellular Ca2+-dependent cascades (Lipton, 2006; Sattler and Tymianski, 2000; Simon et al., 1984).”
BackgroundMethodInfluentialGlasgow, N. G., & Johnson, J. W. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1096-0_2 · Cited by 21
“Thus, identification of NMDAR antagonists selective for NMDARs that may be involved in a pathological state while preserving the function of NMDARs underlying normal function may be vital for successful pharmacological therapy (9-11).”
BackgroundMa, C., Sun, H. Q., Liu, Y., Wang, X.-T., Gao, S., Chen, X.-W., Ma, Z., Wang, G., Shi, Z., & Zheng, Q. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.03.044 · Cited by 21
Adamczyk, A., Czapski, G. A., Wilkaniec, A., & Strosznajder, J. B. (2009) · Pharmacological Reports · doi:10.1016/s1734-1140(09)70170-7 · Cited by 20
Gao, L., Fang, J., Bai, X., Zhou, D., Wang, Y., Liu, A., & Du, G. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12127 · Cited by 20
“Baicalein blocks NMDA-induced extracellular NO decrease S-nitrosylation sites are located toward the extracellular amino-terminus region of NMDA receptor (52).”
BackgroundYu, X., Groveman, B. R., Fang, X., & Lin, S.-X. (2010) · Health · doi:10.4236/health.2010.21002 · Cited by 26
Education Research: Cognitive performance is preserved in sleep-deprived neurology residents
Reimann, M., Manz, R., Prieur, S., Reichmann, H., & Ziemssen, T. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c34a93 · Cited by 22
Lee, Y.-J., Kim, J., Kwak, M.-H., Go, J., Son, H., Kim, D., & Hwang, D. (2013) · Laboratory Animal Research · doi:10.5625/lar.2013.29.2.113 · Cited by 19
“which inhibits brain cell death through excitotoxicity triggered by overstimulation of glutamate receptors [9].”
BackgroundRahim, M. A., & Hossain, M. A. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.112.006098 · Cited by 20
Herrera‐Marschitz, M., Pérez-Lobos, R., Lespay‐Rebolledo, C., Tapia-Bustos, A., Casanova-Ortiz, E., Morales, P., Valdés, J. L., Bustamante, D., & Cassels, B. K. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9795-9 · Cited by 21
“This NO source improved efficacy as a neuroprotectant, compared to that provided by memantine, by nitrosating a redox-mediated regulatory site on the extrasynaptic NMDA receptor (Lipton 2006; Takahashi et al. 2015; see Nakamura and Lipton 2016).”
BackgroundInterplay between Gating and Block of Ligand-Gated Ion Channels
Phillips, M. B., Nigam, A., & Johnson, J. W. (2020) · Brain Sciences · doi:10.3390/brainsci10120928 · Cited by 19
Kellner, S., Abbasi, A., Carmi, I., Heinrich, R., Garin-Shkolnik, T., Hershkovitz, T., Giladi, M., Haitin, Y., Johannesen, K. M., Møller, R. S., et al. (2021) · eLife · doi:10.7554/elife.67555 · Cited by 20
“Nevertheless, in the case of Gain-of-Function (GoF) mutations, there are several exploratory treatments with non-specific GluNR-blockers as primary candidates, notably the FDA-approved drug memantine (Pierson et al., 2014; Strehlow et al., 2019; Amador et al., 2020; Lipton, 2006).”
BackgroundSynthesis and NMDA-receptor affinity of 4-oxo-dexoxadrol derivatives
Sax, M., Ebert, K., Schepmann, D., Wibbeling, B., & Wünsch, B. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.05.020 · Cited by 19
Kovacic, P., & Somanathan, R. (2011) · ISRN Anesthesiology · doi:10.5402/2011/402906 · Cited by 19
“Ketamine is a noncompetitive NMDA receptor antagonist [41].”
BackgroundYang, T., Xu, Z., Liu, W., Xu, B., Deng, Y. L., Li, Y.-H., & Feng, S. (2014) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2014.11.020 · Cited by 21
1‐Benzyl‐1,2,3,4‐Tetrahydro‐β‐Carboline as Channel Blocker ofN‐Methyl‐ d ‐Aspartate Receptors
Espinoza‐Moraga, M., Caballero, J., Gaube, F., Winckler, T., & Santos, L. S. (2012) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2012.01317.x · Cited by 19
“Ligands that specifically antagonize the actions of the neurotransmitter glutamate at NMDA receptors may offer an effective means of novel approach to treat disorders such as Alzheimer's disease (12), cerebral ischemia and stroke (13), epilepsy (14), AIDS-associated dementia (15), Parkinson's disease (16), and Hunting…”
BackgroundZhou, Z., Bai, J., Zhong, S., Zhang, R., Kang, K., Zhang, X., Xu, Y., Zhao, C., & Zhao, M. (2021) · The EPMA Journal · doi:10.1007/s13167-021-00261-2 · Cited by 20
“, memantine) for moderate-to-severe AD [74].”
Combination Therapy for the Treatment of Alzheimer’s Disease: Recent Progress and Future Prospects
Shirbhate, E., Patel, V. K., Tiwari, P., Kore, R., Veerasamy, R., Mishra, A., & Rajak, H. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220907114443 · Cited by 18
Quintans, J. D. S. S., de Brito, R. G., Aquino, P. G. V., França, P. H. B., Siqueira-Lima, P. S., Santana, A. E. G., Ribeiro, Ê. A. N., Salvador, M. J., de Araújo‐Júnior, J. X., & Quintans‐Júnior, L. J. (2014) · Pharmaceutical Biology · doi:10.3109/13880209.2013.870582 · Cited by 18
“The PAG is of physiological relevance to the nociceptive modulation network that operates both at the supraspinal level and through dorsal horn interneurons (Lipton, 2006; Marinelli et al., 2002; Narita et al., 2008; Rodrı́guez-Muñoz et al., 2012).”
BackgroundMacDonald, J. F., & Jackson, M. F. (2007) · Stroke · doi:10.1161/01.str.0000251671.77351.e2 · Cited by 18
Effect of memantine on CBF and CMRO2in patients with early Parkinson’s disease
Borghammer, P., Vafaee, M. S., Østergaard, K., Rodell, A. B., Bailey, C. J., & Cumming, P. D. (2007) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2007.00943.x · Cited by 18
“However, following stronger physiological membrane depolarization, adamantanes (like Mg) leave the channel, thus permitting relatively normal physiological function of the NMDARs in a condition of excitation (3).”
BackgroundHuang, T., Lai, M., Chen, Y.-S., & Huang, C. (2023) · Biomedicines · doi:10.3390/biomedicines11030686 · Cited by 20
“Over-activation of NMDA receptors has been proven to generate excessive Ca2+ influx into neurons, resulting in cellular damage and death [29].”
BackgroundAmyloids of multiple species: are they helpful in survival?
Upadhyay, A., & Mishra, A. (2018) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12399 · Cited by 26
“These molecules obstruct glutamate transmission by binding to N-methyl D-aspartate (NMDA) receptors on neuronal cells, thus reducing overall cell death (Parsons, Danysz & Quack, 1999; Lipton, 2006).”
BackgroundStayte, S., Laloli, K. J., Rentsch, P., Lowth, A., Li, K. M., Pickford, R., & Vissel, B. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113062 · Cited by 17
“…of these drugs to the clinic was not similarly successful as they often result in severe adverse side effects such as psychosis, hallucinations, and impaired learning (Lipton 2006, Johnson et al. 2009), likely due to the effects of altering glutamatergic signaling in healthy areas of the brain.”
BackgroundNeurophysiological biomarkers for schizophrenia therapeutics
Light, G. A., Joshi, Y. B., Molina, J. L., Bhakta, S. G., Nungaray, J. A., Cardoso, L., Kotz, J. E., Thomas, M. L., & Swerdlow, N. R. (2020) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2020.100012 · Cited by 18
“It has little impact on basal NMDA transmission; this distinguishes it mechanistically from other NMDA antagonists [33].”
BackgroundDriver, C., Jackson, T., Lagopoulos, J., & Hermens, D. F. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110609 · Cited by 18
Metadata
- Authors
- Lipton, S. A.
- Affiliations
- Sanford Burnham Prebys Medical Discovery Institute (US)
- Corresponding author
- Lipton, Stuart A.
- ORCID
- Lipton, Stuart A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-01-20
- Volume
- 5
- Issue
- 2
- Pages
- 160-170
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1981238903
- Cited by
- 909
- References
- 98
- Citations by year
- 2026: 39 · 2025: 31 · 2024: 32 · 2023: 31 · 2022: 40 · 2021: 41 · 2020: 51 · 2019: 42 · 2018: 36 · 2017: 40 · 2016: 48 · 2015: 51 · 2014: 47 · 2013: 48 · 2012: 52
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- memantine, NMDA receptor antagonists, neuroprotection, Alzheimer's disease, dementia, glutamate excitotoxicity, calcium influx, free radicals, adverse drug reactions, clinical trial failure, NMDA receptor overactivation
- MeSH terms
- Animals, Humans, Memantine, Neurotoxins, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Antagonists, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.